A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects
Latest Information Update: 15 Jun 2026
At a glance
- Drugs TNX 1500 (Primary) ; Keyhole limpet haemocyanin
- Indications Autoimmune disorders; Graft-versus-host disease; Renal transplant rejection; Transplant rejection
- Focus Adverse reactions; First in man
- Sponsors Tonix Pharmaceuticals Inc
Most Recent Events
- 27 May 2026 Results presented in a Tonix Pharmaceuticals media release.
- 27 May 2026 According to a Tonix Pharmaceuticals media release, company announced the publication of a paper, First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults, in the peer-reviewed Journal of Clinical Immunology.
- 14 Oct 2025 According to a Tonix Pharmaceuticals media release, presentation including data from this study was presented at the 61st Annual Congress of the Japan Society for Transplantation, which took place October 9-11, 2025, in Nagoya, Japan.